Broadly neutralizing antibodies (bNAbs) targeting HIV-1 are of special interest because of their ability to prevent and treat HIV-1 and SHIV infection in humanized mice and nonhuman primates (NHPs), respectively Moldt et al., 2012; Barouch et al., 2013; Klein et al., 2013; Shingai et al., 2013) . Although there was excellent agreement between humanized mice and macaques in passive protection experiments (Balazs et al., 2012; Pietzsch et al., 2012; Shingai et al., 2013) , immunotherapy of established infection was far more effective in macaques infected with SHIV AD8 or SHIV SF162P3 than in humanized mice infected with HIV-1 YU2 . Humanized mice treated with single mAbs showed only a transient drop in viremia with rapid escape caused by selection of antibodyresistant mutants Horwitz et al., 2013) . In contrast, passive transfer experiments of single bNAbs in macaques produced a profound decrease in viremia (Barouch et al., 2013; Shingai et al., 2013) , and prolonged control (Barouch et al., 2013) , with only occasional viral escape (Shingai et al., 2013) . This disparity could be due in part to the host immune system, which is present in the macaques but defective in humanized mice. However, how the host immune system might enhance passive antibody therapy is not known. Here, we investigate the role of the autologous antibody response in suppressing the emergence of viral bNAb escape variants in vivo.
RESULTS AND DISCUSSION
Simultaneous administration of three bNAbs (tri-mix) targeting the CD4-binding site (CD4bs; Antibody-mediated immunotherapy is effective in humanized mice when combinations of broadly neutralizing antibodies (bNAbs) are used that target nonoverlapping sites on the human immunodeficiency virus type 1 (HIV-1) envelope. In contrast, single bNAbs can control simian-human immunodeficiency virus (SHIV) infection in immune-competent macaques, suggesting that the host immune response might also contribute to the control of viremia. Here, we investigate how the autologous antibody response in intact hosts can contribute to the success of immunotherapy. We find that frequently arising antibodies that normally fail to control HIV-1 infection can synergize with passively administered bNAbs by preventing the emergence of bNAb viral escape variants.
To determine whether HIV-1 can escape from all three antibodies when they are administered sequentially, we treated HIV-1 YU2 -infected mice with bNAbs starting with PG16 alone, and added 3BNC117 after 14 d, and 10-1074 after 28 d (Fig. 1 A) . We found a transient reduction (0.18 log 10 to 0.78 log 10 ) of the viral load shortly after each antibody was administered, followed by rapid rebound to baseline viremia (day 42; +0.14 log 10 compared with day 0; Fig. 1 A) . Thus, sequential antibody administration differs from co-administration of the same tri-mix in that sequential therapy fails to control viral replication. 3BNC117; Scheid et al., 2011) , the V1/V2-loop (PG16; Walker et al., 2009) , and the V3-stem (10-1074; effectively suppresses viremia in HIV-1 YU2 -infected humanized mice without the emergence of viral escape variants (Horwitz et al., 2013) . The humanized mice used in the experiments are NOD Rag1 / IL2R NULL mice that are reconstituted with human hematopoietic stem cells. These mice support the development of human T lymphocytes that can be infected with HIV-1 but they do not produce significant antibody responses to the pathogen (Baenziger et al., 2006; Klein et al., 2012) . (A) HIV-1 YU2 -infected mice were sequentially treated with PG16 (orange), PG16, and 3BNC117 (green) and finally with the tri-mix consisting of PG16, 3BNC117, and 10-1074 (blue) as indicated. Graph shows the log 10 change in viral RNA copies in plasma plotted on the y-axis and time in days after starting treatment on the x-axis. The red line shows the mean of changes in viral load. Individual mice IDs are listed at the right. (B) gp120 envelope sequence analysis before and after 14, 28, and 42-49 d of treatment revealed the emergence of HIV-1 YU2 escape variants at the respective target sites of the bNAbs (i.e., PNGS at position N160 for PG16; 280-282 and 458 for 3BNC117; PNGS at position N332 for 10-1074). Each dotted line represents an independent sequence and changes to gp120 YU2 are shown in bold. Red letters and gray highlights indicate regions corresponding to known escape sites as identified in previous monotherapy experiments Horwitz et al., 2013) . Residues in HIV-1 YU2 (top) were numbered according to HXBc2 (bottom) . Presented data were obtained from five treated mice in a single experiment, and sequence information was retrieved and analyzed from at least three mice at each indicated time point.
antibody-resistant HIV-1 YU2 escape variants (Fig. 1 B) . For example, 14 d after starting PG16 therapy, all gp120 sequences analyzed carried mutations at position N160 or T162 that remove the epitope targeted by PG16 (Fig. 1 B) . Sequential addition of 3BNC117 and 10-1074 selected for viral escape Failure to suppress viremia with sequential tri-mix administration suggested that this form of therapy selects for viral variants that are resistant to all three antibodies (Fig. 1 A) . Consistent with this idea, viral envelope sequence analysis at day 0, 14, 28, and 42-49 revealed sequential development of specific Zolla-Pazner, 2005; Scheid et al., 2009) . To determine whether these antibodies with limited activity (tier-1 strains only; here termed tier-1 neutralizing antibodies) are active against viruses that carry bNAb escape mutations, we assayed a panel of 34 tier-1 neutralizing mAbs directed against the V2 or the V3 loop, the CD4bs, the CD4-induced site (CD4i), and gp41 (Scheid et al., 2009; Pietzsch et al., 2010; Mouquet et al., 2011) . Each of these antibodies was tested against WT HIV-1 YU2 and bNAb-resistant variants of HIV-1 YU2 with mutations that naturally arose in in vivo experiments (single mutations: N160K, N332K, and N280Y; HIV-1 YU2 triple mutations: TM1-3; Fig. 4 B; Klein et al., 2012; Horwitz et al., 2013) . Only one of the tier-1 neutralizing antibodies showed activity against the WT HIV-1 YU2 at a very high concentration (IC 50 = 93 µg/ml; Fig. 4 B) . In contrast, three V2 loop-, four V3 loop-, two CD4bs-, and one CD4i-directed antibodies showed activity against the HIV-1 YU2 mutant viruses with IC 50s as low as 0.5 µg/ml (Fig. 4 B) . The three V2 variants that carry mutations in all three antibody target sites (Fig. 1 B; Klein et al., 2012; Horwitz et al., 2013) . Thus, sequential triple bNAb therapy selects for HIV-1 YU2 variants that are resistant to all three bNAbs.
To determine whether tri-mix resistant HIV-1 YU2 retains infectivity we compared infection with WT HIV-1 YU2 and a variant harboring the N160K, N332K, and G458D mutation (HIV-1 YU2 TM2 ). 34 d after infection, HIV-1 YU2 -and HIV-1 YU2 TM2 -infected mice showed geometric mean viral loads of 4.2 log 10 and 5.42 log 10 , respectively (P = 0.0003; Fig. 2 A) . Viremia was long lasting in HIV-1 YU2 TM2 -infected mice (Fig. 2 B) and in most cases the N160K, N332K, and G458D mutations were maintained even in the absence of antibody selection pressure (Fig. 2 C) . Finally, HIV-1 YU2 TM2 -infected mice were resistant to tri-mix therapy (Fig. 2 D) . We concluded that HIV-1 YU2 can escape from sequential tri-mix therapy in vivo without measurable loss of infectivity or impaired viral fitness in humanized mice.
To determine whether chronically SHIV AD8 -infected NHPs or HIV-1-infected humans harbor antibodies that might neutralize bNAb-resistant variants, we assayed plasma/serum samples for neutralizing activity against escape variants in vitro. Plasma samples from chronically SHIV AD8 -infected macaques (Shingai et al., 2012 (Shingai et al., , 2013 were tested against WT SHIV AD8 and SHIV AD8 variants. The SHIV AD8 variants carried either an N332K mutation (SHIV AD8 N332K ) that rendered the virus resistant to the bNAb 10-1074 or the G458D mutation (SHIV AD8 G458D ) that strongly reduced (200-fold) sensitivity to the bNAb 3BNC117. In addition, we included an SHIV AD8 variant that harbored both mutations (N332K-G458D; SHIV AD8 DM ). Although plasma from 16 SHIV AD8 -infected macaques showed varying levels of neutralizing activity against the WT virus SHIV AD8 (Fig. 3 A; ID 50 ), a significant increase in neutralizing activity was detected for bNAb-resistant variants that carried the G458D and the double N332K-G458D mutation (Fig. 3 B) . Moreover, this effect was not specific for SHIV AD8 since even more striking differences were observed for WT HIV-1 YU2 and HIV-1 YU2 triple bNAb escape mutants TM1 (N160K, N332K, and N280Y) and TM2 (N160K, N332K, and G458D; Fig. 3 , A and B). Thus, macaques chronically infected with SHIV AD8 frequently carry antibodies that neutralize the bNAb escape mutants studied.
To determine whether chronically infected humans also have similar antibodies, we tested a collection of 17 serum samples from HIV-1-infected individuals. Similar to macaques, purified IgGs from infected humans showed little or no neutralization against WT HIV-1 YU2 , but increased activity against HIV-1 YU2 TM1 (Fig. 4 A; mean percentage of neutralization at 100 µg/ml total IgG: 2.5 vs. 23.9; P = 0.0004, two-sided MannWhitney U test). Thus, most humans infected with HIV-1 carry antibodies that have demonstrable in vitro neutralizing activity against the studied bNAb-resistant variants of HIV-1 YU2 .
Individuals infected with HIV-1 develop up to 60 different clones of B cells, producing antibodies that have neutralizing activity against easy to neutralize (tier-1) HIV-1 strains but have weak or no activity against more resistant tier-2 primary isolates N332K and G458D, blue) . NHP plasma was also tested against WT HIV-1 YU2 (gray) and HIV-1 YU2 TM1 (N160K, N332K, N280Y, blue) and HIV-1 YU2 TM2 (TM2; N160K, N332K, G458D, blue). (B) Bars represent the mean and SEM of the respective data shown in A. Statistical analysis was performed using a Friedman test followed by Dunn multiple comparison test. Significant differences compared with WT are indicated by asterisks (*, P < 0.05; **, P < 0.001; ***, P < 0.0001). All neutralizing activities were measured in duplicate.
Br ief Definitive Repor t
To determine whether antibodies that neutralize bNAb escape variants can also be elicited by vaccination, we analyzed plasma from NHPs immunized with YU2 gp140-F trimers (Sundling et al., 2010) . Although plasma samples from the vaccinated animals showed little or no neutralizing activity against HIV-1 YU2 (WT; Fig. 4 C) , there was a significant increase loop-directed antibodies were active against HIV-1 YU2 N332K , HIV-1 YU2 TM1 , and HIV-1 YU2 TM2 . The four V3 loop-directed antibodies showed activity against HIV-1 YU2 N280Y , HIV-1 YU2 N160K , HIV-1 YU2 N332K , as well as all three HIV-1 YU2 TMs . Finally, at least one of each of the antibodies targeting CD4bs and CD4i was active against the HIV-1 YU2 TMs in vitro (Fig. 4 B) . mice (2 animals) carried mutations in the same region (Fig. 6 B,  bottom) . In the case of HIV-1 YU2 -infected mice treated with 1-79, we also detected mutations in the V3 crown in some but not all of the sequences in the 3 animals we analyzed, indicating incomplete selection (Fig. 6 C) . In contrast, all sequences obtained from HIV-1 YU2 TM2 -infected mice treated with 1-79 harbored the same K305R mutation (Fig. 6 C) .
HIV-1 YU2 TM2 is an engineered virus that carries bNAb escape mutations that naturally occurred in mice treated with single antibodies Horwitz et al., 2013) . However, it is not a naturally arising strain that might also contain compensatory mutations as part of a heterogeneous swarm. To determine whether combination immunotherapy with a bNAb and a tier-1 neutralizing antibody can delay or suppress emergence of resistant HIV-1 variants during an established infection with a naturally arising strain, we infected humanized mice with HIV-1 YU2 (WT) and treated them with the bNAb 10-1074 alone (Fig. 7 A) or in combination with one of the tier-1 neutralizing antibodies 10-188 (Fig. 7 B) or 1-79 (Fig. 7 C) . Notably, the humanized mice used in our experiments are unable to make a significant humoral immune response to the HIV-1 envelope, and therefore lack any autologous neutralizing antibodies (Baenziger et (Fig. 4 D) . 2 of the 6 antibodies had low levels of activity against HIV-1 YU2 (WT; IC 50s of 33.8 and 49.6 µg/ml), whereas the other four did not reach an IC 50 when measured up to a concentration of 50 µg/ml. In contrast, 5 out of these 6 V3 loop-directed antibodies showed activity against the HIV-1 YU2 single mutants. Moreover, neutralization activity was strongly increased against both HIV-1 YU2 TMs as reflected by IC 50s in the range of 1 µg/ml (Fig. 4 D) . Thus, although tier-1 neutralizing human and macaque anti-HIV-1 antibodies do not neutralize WT HIV-1 YU2 , they are active against bNAb escape variants in TZM-bl assays in vitro.
Of the tested human tier-1 neutralizing antibodies, 10-188 and 1-79 demonstrated the best neutralizing activity against the triple mutated HIV-1 YU2 (Fig. 4 B) . Both antibodies recognize the crown of the V3 loop. Notably, 10-188 and 1-79 bind to different regions of the V3 loop: 1-79 targets the hydrophobic V3 core at aa 307, 309, and 317 (CRA-DLE-type; Burke et al., 2009; Almond et al., 2010; Jiang et al., 2010 ; and unpublished data) and 10-188 targets the V3 -turn at aa 312-314 (LADLE-type; Burke et al., 2009 ). To determine, whether similar antibodies are present in NHPs chronically infected with SHIV AD8, we measured reactivity of plasma samples against selected peptides by ELISA ( Fig. 5 ; Totrov et al., 2010) . All tested NHP sera showed activity against both peptides, demonstrating the presence of CRA-DLE-and LADLE-type antibodies in SHIV AD8 -infected NHPs (Fig. 5) .
To examine the possibility that HIV-1-directed tier-1 neutralizing antibodies can actively suppress viremia in vivo, we infected humanized mice with HIV-1 YU2 (WT) or with HIV-1 YU2 TM2 . Infected mice were treated with either of the tier-1 neutralizing human V3 loop-directed antibodies 10-188 or 1-79. Although only a small effect on the viral load was detected in HIV-1 YU2 -infected mice (Fig. 6 A, left) , a reduction in viremia was observed in mice infected with the mutant virus HIV-1 YU2 TM2 (Fig. 6 A, middle and right). We conclude that the tier-1 neutralizing anti-V3 loop antibodies 10-188 and 1-79 do not alter the viral load in HIV-1 YU2 -infected mice, but can suppress HIV-1 YU2 TM2 infection in vivo. To determine whether 10-188 and 1-79 exerted selective pressure on HIV-1 YU2 and/or HIV-1 YU2 TM2 , we cloned and sequenced cDNA encoding gp120 from HIV-1 YU2 -and HIV-1 YU2 TM2 -infected mice treated with these antibodies. Although 10-188 showed little activity against HIV-1 YU2 in vitro (IC 50 93 µg/ml) and had no measurable effect on the viral load in HIV-1 YU2 -infected mice, 2 out of the 4 mice showed mutations in the -turn in the crown of the V3 loop, which is the epitope targeted by 10-188 (Zolla-Pazner and Cardozo, 2010; Mouquet et al., 2011; Fig. 6 B, top) . In addition, all gp120 sequences analyzed from HIV-1 YU2 TM2 -infected TM2 was analyzed in a single experiment in which each group consisted of at least four individual mice and sequence data were obtained from at least two mice per group. make significant contributions to control HIV-1 infection when combined with potent bNAbs in vivo.
Most individuals infected with HIV-1 develop antibodies that neutralize autologous but not primary heterologous viral strains (Doria-Rose et al., 2009; Simek et al., 2009) . As a result of the rapid rate of viral evolution in the host, the effect of these antibodies on effectively controlling viremia is limited (Schmitz et al., 2003; Miller et al., 2007; Gaufin et al., 2009a,b; Huang et al., 2010) . Nevertheless, these antibodies put selective pressure on HIV-1 as indicated by the emergence of antibodyresistant escape variants (Wei et al., 2003) . Escape from tier-1 neutralizing antibodies frequently involves changes that indirectly conceal the epitope (Ly and Stamatatos, 2000; Wei et al., 2003; Pinter et al., 2004; Blish et al., 2008; Bunnik et al., 2008; . In contrast to monotherapy with any of the three antibodies alone (Figs. 6 A and 7 A), both combinations produced a prolonged and sustained drop in viremia (Fig. 7,  B-D) . Moreover, the combination of 10-1074 and 1-79 continued to suppress viremia below the limit of detection, with no viral escape during 6 wk of therapy (Fig. 7 C) . Escape from 10-1074 monotherapy was associated with N332K/S in 6 out of 6 mice analyzed (Fig. 7 E) . When rebound occurred with the combination of 10-1074 and 10-188, it was associated with selection of mutations in both the 10-1074 and 10-188 target sites at position 332 and the -turn of the V3 crown (position 312-315), respectively (Fig. 7 F) .
We conclude that tier-1 neutralizing antibodies with little demonstrable activity against primary isolates in vitro can Significant differences between treatment groups were determined by using repeated measures ANOVA with a Bonferroni post-hoc test. *, P < 0.05; **, P < 0.001; ***, P < 0.0001). Animals that died before day 42 after treatment start were excluded from statistical analysis. (E) gp120 sequences 14-28 d after the start of 10-1074 treatment. (F) gp120 sequences 35-49 d after the start of treatment with 10-1074 and 10-188. Residues in HIV-1 YU2 (top) were numbered according to HXBc2 (bottom). Treatment combinations were analyzed on 6-10 animals per group in a single round experiment. Sequence data were obtained from at least five individual mice of each analyzed group.
Allergy and Infectious Disease (NIAID) facility and cared for in accordance with standards of the American Association for Accreditation of Laboratory Animal Care (AAALAC) in AAALAC-accredited facilities. All animal procedures were performed according to NIAID animal protocol LMM32, approved by the Institutional Animal Care and Use Committees of NIAID/NIH. The animals used for immunizations were housed at the AAALAC-accredited Astrid Fagraeus Laboratory animal facility in Stockholm in compliance with the guidelines of the Swedish Board of Agriculture. Isolation of mAbs from NHPs was performed essentially as previously described (Sundling et al., 2012a) but by sorting for total Env-specific memory B cells and using optimized primers for amplification of NHP VDJ sequences (Sundling et al., 2012b) . For antibody expression, equal amounts of heavy-and light-chain plasmid DNAs were transfected into FreeStyle 293F cells and the secreted IgGs were purified by protein A-Sepharose columns (GE Healthcare). The specificities of these V3 loop-directed antibodies were determined by ELISA binding analyses using a set of different YU2 Env probes.
Humanized mice. NOD Rag1 / IL2R NULL mice were humanized with hematopoietic stem cells (HSCs), as previously described . In brief, human fetal livers were procured from Advanced Bioscience Resources, Inc. and HSCs were isolated using a CD34 + isolation kit (Stem Cell Technologies, Inc.). Mice (NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl /SzJ) were obtained from The Jackson Laboratory and bred and maintained at the Comparative Bioscience Center of The Rockefeller University. Between 1-5-d-old mice were irradiated with 100 cGy and injected with 2 × 10 5 human HSCs. HSCs used to reconstitute the mice were obtained from human fetal liver tissues of 12 different donors. In the experiments shown, up to 12 humanized mice shared the same donor. Engraftment was evaluated by FACS analysis of the peripheral blood as previously described and mice with successful reconstitution of human lymphocytes were challenged with HIV-1 YU2 or HIV-1 YU2 TM2 . All experiments were performed under approval of the Institutional Review Board and the Institutional Animal Care and Use Committee of The Rockefeller University.
HIV-1 infection. HIV-1 YU2 and HIV-1 YU2 TM2 were produced by transiently transfecting HEK 293T/17 cells using a construct consisting of HIV-1 NL4/3 backbone carrying the HIV-1 YU2 envelope (Zhang et al., 2002) . HIV-1 YU2 TM2 harbors the mutations N160K, N332K, and G458D that were introduced by site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis kit (Agilent Technologies). The concentration of the virus was determined by measuring p24 using the Alliance HIV-1 p24 Antigen ELISA kit (PerkinElmer). Humanized mice were infected by intraperitoneal injection of HIV-1 YU2 or HIV-1 YU2 TM2 viral supernatant containing 110 ng of p24.
Production and administration of mAbs. For mouse treatment experiments we used the following mAbs: PG16 (V1/V2; Walker et al., 2009 Walker et al., ), 10-1074 Mouquet et al., 2012) , 3BNC117 (CD4bs; Scheid et al., 2011), 10-188 (V3-crown; Mouquet et al., 2011) , and 1-79 (V3-crown; Scheid et al., 2009) . With the exception of 3BNC117, all antibodies were produced by transiently transfected HEK 293-6E cells with equal amounts of immunoglobulin heavy and light chain expression vectors. After 7 d, the supernatant was harvested and antibodies were concentrated by ammonium sulfate precipitation. IgG was purified with Protein G-Sepharose 4 Fast Flow. 3BNC117 was produced in CHO cells by Celldex Therapeutics, Inc. All antibodies were filtered (Ultrafree-CL Centrifugal Filters, 0.22 µm; Millipore) and administered s.c. to humanized mice. For treatment of HIV-1-infected mice, 1 mg (each) of 3BNC117, PG16, and 10-1074 was injected as loading dose followed by 0.5 mg of each antibody/mouse twice a week. 10-188 and 1-79 were injected at 4 mg/mouse for the loading dose followed by 2 mg/ mouse twice a week.
HIV-1 plasma viral load. Plasma viral load in HIV-1-infected humanized mice was determined as previously described .
HIV-1 envelope glycoprotein sequence analysis. Total RNA from 100 µl EDTA-plasma was extracted using the MinElute Virus Spin kit (QIAGEN) Bosch et al., 2010; O'Rourke et al., 2010) . For example, the glycan at position N332 can shield the V3 loop from tier-1 neutralizing anti-V3 loop antibodies, but does not alter the antibody target sequence directly (Wei et al., 2003; McCaffrey et al., 2004) . Similarly, glycans at position N276 or N301 can shield the CD4bs from tier-1 neutralizing anti-CD4bs antibodies (Koch et al., 2003; McGuire et al., 2013) . These changes are often favored over direct changes in the target site that might interfere with viral fitness. For example, a glycan can be added to shield the V3 loop without reducing infectivity. This shielding mechanism appears to be preferred over escape mutations in the highly conserved crown of the V3-loop that could interfere with co-receptor binding and alter viral fitness . However, the same glycans that shield V3 also make important contributions to the epitopes of some of the most potent bNAbs, such as 10-1074 or PGT121 (Walker et al., 2011; Mouquet et al., 2012) . These antibodies have profound effects on viremia in NHPs but less so in immune compromised humanized mice when used as a single reagent Barouch et al., 2013; Shingai et al., 2013; Fig. 7 A) . Our data suggest that one of the reasons that escape from 10-1074 or PGT121 immunotherapy in macaques is difficult might be because the autologous antibodies, which are present in macaques but not in humanized mice, prevent escape by the N332 mutation. Interestingly, several of the 10-1074-escape variants in SHIV AD8 -infected NHPs carried a mutation that removes the potential N-linked glycosylation site (PNGS) at position 332 but also generated a new PNGS at position 334 (Shingai et al., 2013) . Therefore, the glycan was shifted from N332 to N334, allowing escape from 10-1074 as well as retaining a glycan at the V3-stem that is likely to protect the V3-loop from autologous antibodies.
Our experiments indicate that HIV-1 infection is in part more readily controlled during immunotherapy in immunocompetent hosts because escape from bNAbs can create holes in the glycan shield that render the virus susceptible to otherwise ineffective autologous antibodies that are present in nearly all infected individuals. Thus, although antibodies with tier-1 neutralizing activity, such as V3 loop-directed monoclonals (Hioe et al., 2010) , generally display weak and sporadic neutralizing activity against most tier-2 viruses, they can effectively synergize with bNAbs in anti-HIV-1 immunotherapy.
MATERIALS AND METHODS
Human samples. Serum samples from HIV-1-infected individuals were collected under informed consent and in accordance with the Institutional Review Board (IRB; protocol number 09-281, University of Cologne, Cologne, Germany). All samples were heat-inactivated for 1 h at 56°C and the IgG fraction was purified with Protein G-Sepharose 4 Fast Flow (GE Healthcare). Sterile filtration and buffer exchange to PBS was performed for all IgGs before testing for neutralizing activity.
Nonhuman primate samples. Plasma samples were obtained from nonhuman primates (NHPs; Macaca mulatta) 90-198 wk after infection with SHIV AD8 (Shingai et al., 2012 (Shingai et al., , 2013 or from uninfected NHPs (Macaca mulatta) before and after immunization with soluble YU2 gp140-F trimers (Yang et al., 2002) , as previously described (Sundling et al., 2010) . SHIV AD8 -infected macaques were housed in a biosafety level 2 National Institute of Neutralization. Neutralizing activities of NHP plasma samples, purified IgGs, and mAbs were determined in a TZM.bl neutralization assay (Li et al., 2005; Seaman et al., 2010) . Mutations in HIV-1 and SHIV envelope glycoprotein sequences were produced using the QuikChange Site-Directed Mutagenesis kit (Agilent Technologies) according to the manufacturer's instructions and used for pseudovirus production. SHIV and HIV-1 pseudovirus mutants included the single mutations SHIV AD8 (N332K), SHIV AD8 (G458D), HIV-1 YU2 (N160K), HIV-1 YU2 (N332K), and HIV-1 YU2 (N280K), as well as the double and triple mutations SHIV AD8 (N160K, N332K), HIV-1 YU2 TM1 (N160K, N332K, N280Y), HIV-1 YU2 TM2 (N160K, N332K, G458D), and HIV-1 YU2 TM3 (N162I, N332K, and N279K).
Statistics.
Statistical significance between IgG neutralizing activity against HIV-1 YU2 wt and HIV-1 YU2 TM2 (Fig. 4 A) , and differences in viral load between HIV-1 YU2 wt and HIV-1 YU2 TM2 -infected mice (Fig. 2 A) was determined by performing a two-sided Mann-Whitney U test in which P < 0.05 was considered significant. Statistical analysis for comparing neutralizing activity of NHP sera against SHIV and HIV-1 variants was performed by Friedman test followed by Dunn multiple comparison. Significant differences in log 10 changes of viral load between mice treated with 10-1074, 10-1074 + 10-188, and 10-1074 + 1-79, as well as HIV-1 YU2 -and HIV-1 YU2 TM2 -infected mice treated with 10-188 or 1-79 were determined by using repeated measures ANOVA with a Bonferroni post-hoc test considering P < 0.05 significant. Sample size of humanized mice in antibody treatment experiments was estimated based on previous results testing single antibodies in HIV-1-infected humanized mice (Horwitz et al., 2013; Klein et al., 2012) . All analyses were performed using GraphPad Prism version 5.0b for Mac OS X, GraphPad Software.
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